Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 10:11:248-257.
doi: 10.33393/grhta.2024.3167. eCollection 2024 Jan-Dec.

Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV

[Article in Italian]
Andrea Marcellusi  1 , Chiara Bini  1 , Francesco Saverio Mennini  1   2 , Silvia Ripoli  3 , Laura Fioravanti  3 , Victoria Federico Paly  4 , Alexa Lina Molinari  4 , Paolo Morelli  5 , Stanimira Krotneva  6 , Shujun Li  7
Affiliations

Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV

[Article in Italian]
Andrea Marcellusi et al. Glob Reg Health Technol Assess. .

Abstract

Objectives:: Advanced Hodgkin’s lymphoma (HL) is a rare severe neoplasm, significantly limiting the ability of patients to do daily activities among other impacts of the cancer. Many adult patients present with advanced stage disease (stages III/IV). This analysis investigates the cost-effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbarzine (AVD) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for the frontline treatment of stage IV HL in Italy based on data from the ECHELON-1 clinical trial.

Methods:: The analysis was conducted from the perspective of the National Health Service using a Markov model with three mutually exclusive health states and a lifetime time horizon. Transition probabilities were taken from the six-year follow-up data of ECHELON-1. Costs were obtained mainly from published literature and national tariffs. For all drugs, ex-factory prices net of the mandatory reductions required by law were considered. Scenarios on possible confidential drug discounts were also explored.

Results:: BV in combination with AVD was associated with an increase of € 44,551 in total costs of 1.03 life-years (LYs) and 0.85 quality-adjusted life-years (QALYs) as compared with ABVD in the base-case scenario. The incremental cost-effectiveness ratio and the incremental cost-utility ratio were estimated equal to € 43,179/LYs and € 52,257/QALYs, respectively, when based on ex-factory prices. BV in combination with AVD was shown to be a cost-effective option in 24 out of 36 scenarios examining possible confidential discounts (ranging from 0% to 60%) for high-cost drugs included in the analysis based on a € 41,411/QALYs threshold for severe diseases.

Conclusions:: Based on data from 6 years of follow-up from the ECHELON-1 trial, BV in combination with AVD has the potential to be a cost-effective option versus ABVD for the frontline treatment of stage IV HL in Italy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: AM, CB and FSM, declare that they have no conflicts of interest. VFP and ALM employment and stock ownership (Takeda). SK and SL are employees of Evidera. SR, LF and PM are employees of Takeda Italia S.p.A.

Figures

FIGURA 1 -
FIGURA 1 -
Struttura del modello di Markov.
FIGURA 2 -
FIGURA 2 -
Piano di costo-efficacia. WTP: Willingness To Pay Threshold. QALYs: Quality Adjusted Life-Years.
See this image and copyright information in PMC

References

    1. Smith A, Crouch S, Lax S et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575–1584. doi: 10.1038/bjc.2015.94. - DOI - PMC - PubMed
    1. Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136(4):E136–E145. doi: 10.1002/ijc.29105. - DOI - PubMed
    1. HMRN R. HMRN incidence – Classical Hodgkin lymphoma. [Accessed June; 2024 ];2022 Online
    1. AIOM. I numeri del cancro in Italia 2023. [Accessed June; 2024 ]. Online
    1. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi: 10.1056/NEJM199309303291402. - DOI - PubMed

LinkOut - more resources